×

Kura Oncology to Present at the Oppenheimer 2015 Healthcare Conference

LA JOLLA, Calif., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will present an overview of the company at 10:55 a.m. EST (7:55 a.m. PST) on Tuesday, December 8th, at the Oppenheimer 26th Annual Healthcare Conference in New York. The conference will be held at the Westin Grand Central Hotel, New York City.

A live audio webcast and replay will be available in the Investors section of Kura Oncology's corporate website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura's pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor that is currently in three Phase 2 clinical studies: the first study in patients with locally advanced solid tumors that carry HRAS mutations; the second study in patients with peripheral T-cell lymphomas; and the third study, an investigator-sponsored Phase 2 trial, in patients with urothelial carcinoma tumors characterized by HRAS mutations. Kura's preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program. More information about Kura Oncology may be found at www.kuraoncology.com.

CONTACT: INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 robert.uhl@westwicke.com CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849 5375 mark@canalecomm.com

Source:Kura Oncology